

Paul M Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4482252/publications.pdf>

Version: 2024-02-01

255
papers

7,327
citations

50276

46
h-index

98798

67
g-index

259
all docs

259
docs citations

259
times ranked

6302
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent advances in curcumin nanoformulation for cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1183-1201.	5.0	186
2	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. <i>Pharmaceutics</i> , 2019, 11, 113.	4.5	165
3	Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 2513-2522.	5.2	148
4	The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. <i>International Journal of Pharmaceutics</i> , 2002, 246, 47-59.	5.2	144
5	Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 481-489.	9.1	133
6	Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1009-1026.	5.0	121
7	Visualization of the crystallization of lactose from the amorphous state. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 155-164.	3.3	108
8	The influence of dose on the performance of dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2005, 296, 26-33.	5.2	108
9	Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. <i>Pharmaceutical Research</i> , 2007, 24, 963-970.	3.5	103
10	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 1207-1214.	2.0	98
11	The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfate's Lactose Interactions in DPI Formulations. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 992-1001.	2.0	90
12	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 145-152.	4.3	90
13	Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 239-247.	4.0	90
14	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 285-292.	4.3	86
15	Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 305-315.	2.9	83
16	Solid lipid microparticles as an approach to drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 583-599.	5.0	82
17	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 35, 12-18.	4.0	80
18	Agglomerate Strength and Dispersion of Salmeterol Xinafoate from Powder Mixtures for Inhalation. <i>Pharmaceutical Research</i> , 2006, 23, 2556-2565.	3.5	76

#	ARTICLE	IF	CITATIONS
19	Delivery of antibiotics to the respiratory tract: an update. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 897-905.	5.0	76
20	Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. <i>Pharmaceutical Research</i> , 2012, 29, 3335-3346.	3.5	75
21	The Influence of Drug Morphology on Aerosolisation Efficiency of Dry Powder Inhaler Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2780-2788.	3.3	74
22	Superhydrophobic, nanotextured polyvinyl chloride films for delaying <i>Pseudomonas aeruginosa</i> attachment to intubation tubes and medical plastics. <i>Acta Biomaterialia</i> , 2012, 8, 1881-1890.	8.3	74
23	Investigation into the Effect of Humidity on Drug-Drug Interactions Using the Atomic Force Microscope. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 815-822.	3.3	70
24	The use of computational approaches in inhaler development. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 312-322.	13.7	69
25	A Review of Respiratory Anatomical Development, Air Flow Characterization and Particle Deposition. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 380.	2.6	68
26	Cospray Dried Antibiotics for Dry Powder Lung Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3356-3366.	3.3	67
27	The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 22, 235-240.	4.0	66
28	Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy. <i>AAPS Journal</i> , 2009, 11, 771-778.	4.4	64
29	Pharmaceutical applications of the Calu-3 lung epithelia cell line. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1287-1302.	5.0	63
30	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 453-466.	5.0	62
31	The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1331-1341.	3.3	60
32	The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. <i>AAPS PharmSciTech</i> , 2004, 5, 69-74.	3.3	57
33	The potential to treat lung cancer via inhalation of repurposed drugs. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 107-130.	13.7	57
34	Pulmonary Spray Dried Powders of Tobramycin Containing Sodium Stearate to Improve Aerosolization Efficiency. <i>Pharmaceutical Research</i> , 2009, 26, 1084-1092.	3.5	56
35	Surface Energy and Interparticle Force Correlation in Model pMDI Formulations. <i>Pharmaceutical Research</i> , 2005, 22, 816-825.	3.5	54
36	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. , 2014, 144, 235-252.		54

#	ARTICLE	IF	CITATIONS
37	The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 285-293.	13.7	53
38	Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 278-285.	4.0	53
39	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 107, 223-233.	4.3	53
40	The Influence of Relative Humidity on the Cohesion Properties of Micronized Drugs Used in Inhalation Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 753-761.	3.3	51
41	Particle size dependence of polymorphism in spray-dried mannitol. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 41-48.	4.0	51
42	Deposition, Diffusion and Transport Mechanism of Dry Powder Microparticulate Salbutamol, at the Respiratory Epithelia. <i>Molecular Pharmaceutics</i> , 2012, 9, 1717-1726.	4.6	51
43	Particle Aerosolisation and Break-up in Dry Powder Inhalers 1: Evaluation and Modelling of Venturi Effects for Agglomerated Systems. <i>Pharmaceutical Research</i> , 2010, 27, 1367-1376.	3.5	50
44	Lactose Composite Carriers for Respiratory Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 802-810.	3.5	49
45	Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2535-2540.	3.2	49
46	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 88-94.	4.0	47
47	Magnetised Thermo Responsive Lipid Vehicles for Targeted and Controlled Lung Drug Delivery. <i>Pharmaceutical Research</i> , 2012, 29, 2456-2467.	3.5	47
48	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 83-89.	4.3	46
49	The Effect of Mechanical Processing on Surface Stability of Pharmaceutical Powders: Visualization by Atomic Force Microscopy. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 611-620.	3.3	45
50	Effect of Humidity on Aerosolization of Micronized Drugs. <i>Drug Development and Industrial Pharmacy</i> , 2003, 29, 959-966.	2.0	45
51	Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1205-1220.	5.0	45
52	Epithelial Profiling of Antibiotic Controlled Release Respiratory Formulations. <i>Pharmaceutical Research</i> , 2011, 28, 2327-2338.	3.5	45
53	A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. <i>Pharmaceutical Research</i> , 2014, 31, 1239-1253.	3.5	44
54	Primary Air-liquid Interface Culture of Nasal Epithelium for Nasal Drug Delivery. <i>Molecular Pharmaceutics</i> , 2016, 13, 2242-2252.	4.6	44

#	ARTICLE	IF	CITATIONS
55	Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. <i>Journal of Colloid and Interface Science</i> , 2003, 262, 298-302.	9.4	43
56	The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2011, 416, 129-135.	5.2	43
57	A Novel Inhalable Form of Rifapentine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1411-1421.	3.3	43
58	Silver nanoparticles enhance <i>Pseudomonas aeruginosa</i> PAO1 biofilm detachment. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 719-729.	2.0	43
59	Overcoming Dose Limitations Using the Orbital [®] Multi-Breath Dry Powder Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 138-147.	1.4	42
60	Non-cytotoxic silver nanoparticle-polyvinyl alcohol hydrogels with anti-biofilm activity: designed as coatings for endotracheal tube materials. <i>Biofouling</i> , 2014, 30, 773-788.	2.2	41
61	On the physical transformations of processed pharmaceutical solids. <i>Micron</i> , 2005, 36, 519-524.	2.2	40
62	The Use of Organic Vapor Sorption to Determine Low Levels of Amorphous Content in Processed Pharmaceutical Powders. <i>Drug Development and Industrial Pharmacy</i> , 2007, 33, 91-97.	2.0	40
63	Surface Energy of Microcrystalline Cellulose Determined by Capillary Intrusion and Inverse Gas Chromatography. <i>AAPS Journal</i> , 2008, 10, 494-503.	4.4	40
64	Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. <i>International Journal of Pharmaceutics</i> , 2011, 413, 1-9.	5.2	40
65	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. <i>Journal of Aerosol Science</i> , 2008, 39, 82-93.	3.8	39
66	Continued Investigation Into the Influence of Loaded Dose on the Performance of Dry Powder Inhalers: Surface Smoothing Effects. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1135-1138.	2.0	38
67	Synthesis and Characterization of Inhalable Flavonoid Nanoparticle for Lung Cancer Cell Targeting. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 371-386.	1.1	38
68	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. <i>AAPS PharmSciTech</i> , 2019, 20, 299.	3.3	38
69	Comparative study of erythritol and lactose monohydrate as carriers for inhalation: Atomic force microscopy and in vitro correlation. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 243-251.	4.0	36
70	The Influence of Flow Rate on the Aerosol Deposition Profile and Electrostatic Charge of Single and Combination Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 2639-2646.	3.5	36
71	Role of Agglomeration in the Dispersion of Salmeterol Xinafoate from Mixtures for Inhalation with Differing Drug to Fine Lactose Ratios. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 3140-3152.	3.3	35
72	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 486-495.	4.3	35

#	ARTICLE	IF	CITATIONS
73	Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection. <i>Molecular Pharmaceutics</i> , 2015, 12, 2001-2009.	4.6	35
74	From single excipients to dual excipient platforms in dry powder inhaler products. <i>International Journal of Pharmaceutics</i> , 2016, 514, 374-383.	5.2	35
75	Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 86, 20-28.	4.0	35
76	Novel Temperature Controlled Surface Dissolution of Excipient Particles for Carrier Based Dry Powder Inhaler Formulations. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 243-251.	2.0	34
77	Preparation and Evaluation of Controlled Release Microparticles for Respiratory Protein Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2709-2717.	3.3	34
78	Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment. <i>Pharmaceutics</i> , 2021, 13, 9.	4.5	34
79	In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2014, 31, 1779-1787.	3.5	33
80	Inhaled gene delivery: a formulation and delivery approach. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 319-330.	5.0	33
81	The utility of 3D-printed airway stents to improve treatment strategies for central airway obstructions. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1-10.	2.0	33
82	Introduction of the Electrical Next Generation Impactor (eNGI) and Investigation of its Capabilities for the Study of Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 431-437.	3.5	32
83	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. <i>International Journal of Pharmaceutics</i> , 2015, 491, 190-197.	5.2	32
84	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 1660-1668.	2.0	32
85	In Vitro Investigation of Drug Particulates Interactions and Aerosol Performance of Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2006, 24, 125-135.	3.5	30
86	Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 347-354.	4.0	30
87	The use of colloid probe microscopy to predict aerosolization performance in dry powder inhalers: AFM and in vitro correlation. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1800-1809.	3.3	29
88	A review of co-milling techniques for the production of high dose dry powder inhaler formulation. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1229-1238.	2.0	29
89	The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation. <i>Aerosol Science and Technology</i> , 2006, 40, 227-236.	3.1	28
90	Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. <i>International Journal of Pharmaceutics</i> , 2006, 320, 58-63.	5.2	27

#	ARTICLE	IF	CITATIONS
91	Influence of Storage Relative Humidity on the Dispersion of Salmeterol Xinafoate Powders for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1015-1027.	3.3	27
92	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 183-193.	5.0	27
93	Dynamic Vapor Sorption Properties of Sodium Starch Glycolate Disintegrants. <i>Pharmaceutical Development and Technology</i> , 2005, 10, 249-259.	2.4	26
94	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1625-1637.	2.0	26
95	Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 31-37.	4.3	26
96	Scanning White-Light Interferometry as a Novel Technique to Quantify the Surface Roughness of Micron-Sized Particles for Inhalation. <i>Langmuir</i> , 2008, 24, 11307-11312.	3.5	25
97	Particle Aerosolisation and Break-up in Dry Powder Inhalers: Evaluation and Modelling of the Influence of Grid Structures for Agglomerated Systems. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4710-4721.	3.3	25
98	Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in Pulmonary Diseases. <i>AAPS Journal</i> , 2014, 16, 269-280.	4.4	25
99	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1510-1518.	2.0	25
100	Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: An AFM and Raman investigation. <i>Journal of Colloid and Interface Science</i> , 2011, 361, 649-655.	9.4	24
101	Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 375-387.	3.1	24
102	Drug delivery for tuberculosis: is inhaled therapy the key to success?. <i>Therapeutic Delivery</i> , 2017, 8, 819-821.	2.2	24
103	Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 37, 442-450.	4.0	23
104	Does electrostatic charge affect powder aerosolisation?. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2455-2461.	3.3	23
105	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 853-857.	2.8	23
106	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: Implications in the treatment of chronic obstructive airway pathologies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 84, 566-572.	4.3	23
107	Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. <i>Respirology</i> , 2013, 18, 1197-1201.	2.3	23
108	Repurposing of statins via inhalation to treat lung inflammatory conditions. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 93-106.	13.7	23

#	ARTICLE	IF	CITATIONS
109	The Development of a Novel High-Dose Pressurized Aerosol Dry-Powder Device (PADD) for the Delivery of Pumactant for Inhalation Therapy. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2004, 17, 123-128.	1.2	22
110	Recent Advances in Controlled Release Pulmonary Therapy. <i>Current Drug Delivery</i> , 2009, 6, 404-414.	1.6	22
111	Preparation and <i>in vitro</i> evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. <i>Journal of Microencapsulation</i> , 2012, 29, 225-233.	2.8	22
112	The Effects of Mannitol on the Transport of Ciprofloxacin across Respiratory Epithelia. <i>Molecular Pharmaceutics</i> , 2013, 10, 2915-2924.	4.6	22
113	Dry powder formulation of simvastatin. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 857-868.	5.0	22
114	Dosing challenges in respiratory therapies. <i>International Journal of Pharmaceutics</i> , 2018, 548, 659-671.	5.2	22
115	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of Impaction Effects for Agglomerated Systems. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2744-2754.	3.3	21
116	Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 980-988.	2.0	21
117	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 937-957.	5.0	21
118	Chemical characterisation of sodium starch glycolate particles. <i>International Journal of Pharmaceutics</i> , 2002, 240, 67-78.	5.2	20
119	Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. <i>International Journal of Pharmaceutics</i> , 2012, 438, 150-159.	5.2	20
120	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 859-865.	2.0	20
121	Limitations of high dose carrier based formulations. <i>International Journal of Pharmaceutics</i> , 2018, 544, 141-152.	5.2	20
122	Euler-Lagrange approach to investigate respiratory anatomical shape effects on aerosol particle transport and deposition. <i>Toxicology Research and Application</i> , 2019, 3, 239784731989467.	0.6	20
123	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles <i>in vitro</i> . <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 38-45.	4.3	19
124	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2016, 514, 392-398.	5.2	19
125	The use of fatty acids as absorption enhancer for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2018, 541, 93-100.	5.2	19
126	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An <i>in vitro</i> study. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 120, 96-106.	4.0	19

#	ARTICLE	IF	CITATIONS
127	The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems. <i>Pharmaceutical Research</i> , 2010, 27, 1325-1336.	3.5	18
128	Modelling of molecular phase transitions in pharmaceutical inhalation compounds: An in silico approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 83-89.	4.3	18
129	Salbutamol Sulfate Absorption Across Calu-3 Bronchial Epithelia Cell Monolayer is Inhibited in the Presence of Common Anionic NSAIDs. <i>Journal of Asthma</i> , 2013, 50, 334-341.	1.7	18
130	Incorporation of quercetin in respirable lipid microparticles: Effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013, 112, 322-329.	5.0	18
131	Novel Simvastatin Inhalation Formulation and Characterisation. <i>AAPS PharmSciTech</i> , 2014, 15, 956-962.	3.3	18
132	Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. <i>Clinical Science</i> , 2017, 131, 499-509.	4.3	18
133	Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 142, 105098.	4.0	18
134	In-vitro and particle image velocimetry studies of dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2021, 592, 119966.	5.2	18
135	The potential use of raman mapping to investigate in vitro deposition of combination pressurized metered-dose inhalers. <i>AAPS Journal</i> , 2004, 6, 41-44.	4.4	17
136	Understanding lactose behaviour during storage by monitoring surface energy change using inverse gas chromatography. <i>Dairy Science and Technology</i> , 2010, 90, 271-285.	2.2	17
137	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. <i>Journal of Controlled Release</i> , 2010, 146, 54-60.	9.9	17
138	Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1245-1253.	2.4	17
139	Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 320-327.	4.3	17
140	Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells. <i>Pharmaceutical Research</i> , 2016, 33, 92-101.	3.5	17
141	Inhaled simvastatin nanoparticles for inflammatory lung disease. <i>Nanomedicine</i> , 2017, 12, 2471-2485.	3.3	17
142	Microfluidic production of endoskeleton droplets with controlled size and shape. <i>Powder Technology</i> , 2018, 329, 129-136.	4.2	17
143	Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 427-442.	2.0	17
144	The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2014, 443, 345-355.	4.7	16

#	ARTICLE	IF	CITATIONS
145	Inhalable tranexamic acid for haemoptysis treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 311-319.	4.3	16
146	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. <i>Molecular Pharmaceutics</i> , 2015, 12, 2625-2632.	4.6	16
147	Delivery of theophylline as dry powder for inhalation. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 520-527.	9.1	16
148	Curcumin Nanoparticles Attenuate Production of Pro-inflammatory Markers in Lipopolysaccharide-Induced Macrophages. <i>Pharmaceutical Research</i> , 2016, 33, 315-327.	3.5	16
149	A Novel Apparatus for the Determination of Solubility in Pressurized Metered Dose Inhalers. <i>Drug Development and Industrial Pharmacy</i> , 2006, 32, 1159-1163.	2.0	15
150	Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1913-1932.	1.8	15
151	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 76, 68-72.	4.0	15
152	Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 135-143.	2.1	15
153	High-Speed Laser Image Analysis of Plume Angles for Pressurised Metered Dose Inhalers: The Effect of Nozzle Geometry. <i>AAPS PharmSciTech</i> , 2017, 18, 782-789.	3.3	15
154	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 156, 121-130.	4.3	15
155	Real-time quantitative monitoring of <i>in vitro</i> nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 803-818.	5.0	15
156	A Review of Electrostatic Measurement Techniques for Aerosol Drug Delivery to the Lung: Implications in Aerosol Particle Deposition. <i>Journal of Adhesion Science and Technology</i> , 2011, 25, 385-405.	2.6	14
157	Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles. <i>Pharmaceutical Development and Technology</i> , 2013, 18, 266-273.	2.4	14
158	A Novel High-Speed Imaging Technique to Predict the Macroscopic Spray Characteristics of Solution Based Pressurised Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2014, 31, 2963-2974.	3.5	14
159	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 319-323.	2.5	14
160	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. <i>Pharmaceutical Development and Technology</i> , 2015, 20, 897-910.	2.4	14
161	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 83, 45-51.	4.0	14
162	Motivations and Key Features for a Wearable Device for Continuous Monitoring of Breathing: A Web-Based Survey. <i>JMIR Biomedical Engineering</i> , 2017, 2, e1.	1.2	14

#	ARTICLE	IF	CITATIONS
163	The use of atomic force microscopy to study the conditioning of micronised budesonide. <i>International Journal of Pharmaceutics</i> , 2008, 357, 314-317.	5.2	13
164	Mannitol Delivery by Vibrating Mesh Nebulisation for Enhancing Mucoiliary Clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2693-2702.	3.3	13
165	A "soft spot"™ for drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. <i>Journal of Materials Chemistry B</i> , 2015, 3, 2583-2589.	5.8	13
166	Implications and emerging control strategies for ventilator-associated infections. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 379-393.	4.4	13
167	Immunomodulatory Effects of a Low-Dose Clarithromycin-Based Macrolide Solution Pressurised Metered Dose Inhaler. <i>Pharmaceutical Research</i> , 2015, 32, 2144-2153.	3.5	13
168	Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays. <i>Pharmaceutical Research</i> , 2016, 33, 816-825.	3.5	13
169	Revealing pMDI Spray Initial Conditions: Flashing, Atomisation and the Effect of Ethanol. <i>Pharmaceutical Research</i> , 2017, 34, 718-729.	3.5	13
170	On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2021, 38, 277-288.	3.5	13
171	Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges. <i>Food and Chemical Toxicology</i> , 2022, 163, 112976.	3.6	13
172	Delivery of High Solubility Polyols by Vibrating Mesh Nebulizer to Enhance Mucoiliary Clearance. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 297-305.	1.4	12
173	Isothermal calorimetry: A predictive tool to model drug-propellant interactions in pressurized metered dose systems. <i>International Journal of Pharmaceutics</i> , 2014, 461, 301-309.	5.2	12
174	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. <i>RSC Advances</i> , 2016, 6, 25789-25798.	3.6	12
175	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and <i>in vitro</i> deposition study. <i>Journal of Microencapsulation</i> , 2016, 33, 735-742.	2.8	12
176	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1407-1420.	5.0	12
177	Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3890-3897.	3.3	12
178	Microstructural Analysis of Porous Composite Materials: Dynamic Imaging of Drug Dissolution and Diffusion Through Porous Matrices. <i>AAPS Journal</i> , 2008, 10, 560-564.	4.4	11
179	The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. <i>Journal of Aerosol Science</i> , 2009, 40, 324-337.	3.8	11
180	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 639-645.	2.4	11

#	ARTICLE	IF	CITATIONS
181	The role of direct support professionals in asthma management. <i>Journal of Intellectual and Developmental Disability</i> , 2015, 40, 342-353.	1.6	11
182	Tuning Aerosol Performance Using the Multibreath Orbital® Dry Powder Inhaler Device: Controlling Delivery Parameters and Aerosol Performance via Modification of Puck Orifice Geometry. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2169-2176.	3.3	11
183	Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 30-38.	2.6	11
184	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. <i>Pharmaceutical Research</i> , 2018, 35, 50.	3.5	11
185	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2964-2971.	3.3	11
186	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. <i>International Journal of Pharmaceutics</i> , 2019, 558, 341-350.	5.2	11
187	The Influence of Actuator Materials and Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI) Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 1325-1337.	3.5	10
188	Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. <i>Australian Journal of Primary Health</i> , 2014, 20, 278.	0.9	10
189	Drug Release from Inert Spherical Matrix Systems Using Monte Carlo Simulations. <i>Current Drug Delivery</i> , 2017, 14, 65-72.	1.6	10
190	Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler®. <i>Drug Development and Industrial Pharmacy</i> , 2011, 37, 1365-1375.	2.0	9
191	A locally constrained statistical shape model for robust nasal cavity segmentation in computed tomography. , 2016, , .		9
192	Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. <i>Pharmaceutical Research</i> , 2016, 33, 1249-1258.	3.5	9
193	The ability of people with intellectual disability to use inhalers “an exploratory mixed methods study. <i>Journal of Asthma</i> , 2016, 53, 86-93.	1.7	9
194	An automated segmentation framework for nasal computational fluid dynamics analysis in computed tomography. <i>Computers in Biology and Medicine</i> , 2019, 115, 103505.	7.0	9
195	Drug distribution transients in solution and suspension-based pressurised metered dose inhaler sprays. <i>International Journal of Pharmaceutics</i> , 2019, 566, 463-475.	5.2	9
196	Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. <i>Pharmaceutical Research</i> , 2020, 37, 186.	3.5	9
197	Understanding the effects of aerodynamic and hydrodynamic shear forces on <i>Pseudomonas aeruginosa</i> biofilm growth. <i>Biotechnology and Bioengineering</i> , 2022, 119, 1483-1497.	3.3	9
198	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. <i>Physica B: Condensed Matter</i> , 2007, 394, 315-319.	2.7	8

#	ARTICLE	IF	CITATIONS
199	Combining experimental and computational techniques to understand and improve dry powder inhalers. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 59-73.	5.0	8
200	Development of an In Vivo Ovine Dry Powder Inhalation Model for the Evaluation of Conventional and Controlled Release Microparticles. <i>AAPS Journal</i> , 2009, 11, 465-8.	4.4	7
201	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. <i>Drug Delivery and Translational Research</i> , 2014, 4, 256-267.	5.8	7
202	Investigation into physical and chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. <i>Pharmaceutical Development and Technology</i> , 2014, 19, 911-921.	2.4	7
203	Determination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1661-1675.	5.0	7
204	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. <i>Journal of Drug Targeting</i> , 2017, 25, 342-349.	4.4	7
205	Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler. <i>AAPS PharmSciTech</i> , 2019, 20, 94.	3.3	7
206	Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1631-1645.	5.0	7
207	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. <i>Nanomedicine</i> , 2020, 15, 1947-1963.	3.3	7
208	Parameters affecting drug release from inert matrices. 1: Monte Carlo simulation. <i>Pharmaceutical Development and Technology</i> , 2012, 17, 344-352.	2.4	6
209	Evolved gas analysis during thermal degradation of salbutamol sulphate. <i>Journal of Thermal Analysis and Calorimetry</i> , 2015, 120, 789-794.	3.6	6
210	Exploring the impact of sample flowrate on in vitro measurements of metered dose inhaler performance. <i>International Journal of Pharmaceutics</i> , 2016, 514, 420-427.	5.2	6
211	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size. <i>Nanomedicine</i> , 2020, 15, 1927-1945.	3.3	6
212	Effect of continuous positive airway pressure treatment on permeability, inflammation and mucus production of human epithelial cells. <i>ERJ Open Research</i> , 2020, 6, 00327-2019.	2.6	6
213	Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120319.	5.2	6
214	Increasing the fine particle fraction of pressurised metered dose inhaler solutions with novel actuator shapes. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120341.	5.2	6
215	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. <i>Bioengineering</i> , 2021, 8, 110.	3.5	6
216	An adaptable microreactor to investigate the influence of interfaces on <i>Pseudomonas aeruginosa</i> biofilm growth. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 1067-1077.	3.6	6

#	ARTICLE	IF	CITATIONS
217	Interaction of Moisture with Sodium Starch Glycolate. <i>Pharmaceutical Development and Technology</i> , 2007, 12, 211-216.	2.4	5
218	Aerosol Tribocharging and its Relation to the Deposition of Oxisâ„¢ Turbuhaler® in the Electrical Next Generation Impactor. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 5270-5280.	3.3	5
219	Twenty years of HFA pMDI patents: facts and perspectives. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1209-1216.	2.4	5
220	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2015, 32, 2928-2936.	3.5	5
221	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. <i>AAPS PharmSciTech</i> , 2018, 19, 3272-3276.	3.3	5
222	Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. <i>Pharmaceutical Research</i> , 2019, 36, 14.	3.5	5
223	Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121989.	5.2	5
224	Modification of Disodium Cromoglycate Passage Across Lung Epithelium In Vitro Via Incorporation into Polymeric Microparticles. <i>AAPS Journal</i> , 2012, 14, 79-86.	4.4	4
225	Preparation and Evaluation of Single and Co-Engineered Combination Inhalation Carrier Formulations for the Treatment of Asthma. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4267-4276.	3.3	4
226	The Effect of Actuator Nozzle Designs on the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols. <i>Pharmaceutical Research</i> , 2015, 32, 1237-1248.	3.5	4
227	Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate. <i>AAPS PharmSciTech</i> , 2017, 18, 2248-2259.	3.3	4
228	Using individualized three-dimensional printed airway models to guide airway stent implantation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 900-903.	1.1	4
229	Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1729-1733.	2.0	4
230	Dynamic Vapor Sorption Properties of Sodium Starch Glycolate Disintegrants. <i>Pharmaceutical Development and Technology</i> , 2005, 10, 249-259.	2.4	4
231	The Formation of Aerosol Particles from Solution-Based Pressurized Metered Dose Inhalers and Implications of Incomplete Droplet Drying: Theoretical and Experimental Comparison. <i>Aerosol Science and Technology</i> , 2015, 49, 1090-1099.	3.1	3
232	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 69-84.	0.8	3
233	Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 949-959.	3.3	3
234	Simulation of respiratory tract lining fluid for in vitro dissolution study. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1091-1100.	5.0	3

#	ARTICLE	IF	CITATIONS
235	The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 103-108.	1.4	3
236	Effect of Moisture on the Compressibility and Compactibility of Sodium Starch Glycolate. <i>Pharmaceutical Development and Technology</i> , 2007, 12, 217-222.	2.4	2
237	Determination of Reference Ultrasound Parameters for Model and Hydrofluoroalkane Propellants Using High-Resolution Ultrasonic Spectroscopy. <i>AAPS PharmSciTech</i> , 2008, 9, 605-611.	3.3	2
238	Comparative Measurements of Pressurised Metered Dose Inhaler (pMDI) Stem Displacement. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 90-94.	2.0	2
239	Computational and visualization approaches in respiratory delivery. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 295.	13.7	2
240	Image-based ciliary beating frequency estimation for therapeutic assessment on defective mucociliary clearance diseases. , 2014, , .		2
241	The Effects of Loaded Carrier Mass and Formulation Mass on Aerosolization Efficiency in Dry Powder Inhaler Devices. <i>Current Drug Delivery</i> , 2015, 12, 40-46.	1.6	2
242	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1401-1403.	3.3	2
243	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. <i>European Journal of Pharmacology</i> , 2021, 902, 174098.	3.5	2
244	Application of Micro-Engineered Kidney, Liver, and Respiratory System Models to Accelerate Preclinical Drug Testing and Development. <i>Bioengineering</i> , 2022, 9, 150.	3.5	2
245	Characterization of the surface physico-chemical stability of materials directly applicable to inhalation therapy. , 0, , .		1
246	Correlation between compactibility values and excipient cluster size using an <i>in silico</i> approach. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 374-381.	2.0	1
247	Unique location but similar issues: working with health professionals in correctional services to improve inhaler use. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 276-281.	0.8	1
248	Beating cilia identification in fluorescence microscope images for accurate CBF measurement. , 2015, , .		1
249	The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment. , 2017, , 25-82.		1
250	Selective shape-change response by anisotropic endoskeletal droplets. <i>Extreme Mechanics Letters</i> , 2020, 35, 100618.	4.1	1
251	Particle Image Velocimetry Measurements of a Dry Powder Inhaler Flow. <i>International Symposium on Particle Image Velocimetry</i> , 2021, 1, .	0.1	1
252	Prospective nanoparticle treatments for lymphangioleiomyomatosis. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 75-86.	5.0	1

#	ARTICLE	IF	CITATIONS
253	Themed Issue: Inhalation Pharmaceuticals â€œ Current Technologies and Approaches to Respiratory Drug Delivery. Journal of Pharmacy and Pharmacology, 2012, 64, 1207-1208.	2.4	0
254	Reduced Sleep Quality Correlates with Worse Hyperinflation in Patients with Chronic Obstructive Pulmonary Disease. , 2019, , .		0
255	Investigating potential TRPV1 positive feedback to explain TRPV1 upregulation in airway disease states. Drug Development and Industrial Pharmacy, 2022, , 1-11.	2.0	0